• M Roulaud, I Durand-Zaleski, P Ingrand, A Serrie, B Diallo, P Peruzzi, P D Hieu, J Voirin, S Raoul, P Page, D Fontaine, M Lantéri-Minet, S Blond, N Buisset, E Cuny, M Cadenne, F Caire, D Ranoux, P Mertens, H Naous, E Simon, E Emery, B Gadan, J Regis, J-C Sol, G Béraud, F Debiais, G Durand, F Guetarni Ging, A Prévost, C Brandet, O Monlezun, A Delmotte, S d'Houtaud, B Bataille, and P Rigoard.
• N(3)lab (Neuromodulation and Neural Networks), Inserm CIC 802, Poitiers University Hospital, 86000 Poitiers, France. Electronic address: manuel.roulaud@chu-poitiers.fr.
• Neurochirurgie. 2015 Mar 1; 61 Suppl 1: S109-16.

BackgroundMany studies have demonstrated the efficacy of spinal cord stimulation (SCS) for chronic neuropathic radicular pain over recent decades, but despite global favourable outcomes in failed back surgery syndrome (FBSS) with leg pain, the back pain component remains poorly controlled by neurostimulation. Technological and scientific progress has led to the development of new SCS leads, comprising a multicolumn design and a greater number of contacts. The efficacy of multicolumn SCS lead configurations for the treatment of the back pain component of FBSS has recently been suggested by pilot studies. However, a randomized controlled trial must be conducted to confirm the efficacy of new generation multicolumn SCS. Évaluation médico-économique de la STImulation MEdullaire mulTi-colonnes (ESTIMET) is a multicentre, randomized study designed to compare the clinical efficacy and health economics aspects of mono- vs. multicolumn SCS lead programming in FBSS patients with radicular pain and significant back pain.Materials And MethodsFBSS patients with a radicular pain VAS score≥50mm, associated with a significant back pain component were recruited in 14 centres in France and implanted with multicolumn SCS. Before the lead implantation procedure, they were 1:1 randomized to monocolumn SCS (group 1) or multicolumn SCS (group 2). Programming was performed using only one column for group 1 and full use of the 3 columns for group 2. Outcome assessment was performed at baseline (pre-implantation), and 1, 3, 6 and 12months post-implantation. The primary outcome measure was a reduction of the severity of low back pain (bVAS reduction≥50%) at the 6-month visit. Additional outcome measures were changes in global pain, leg pain, paraesthesia coverage mapping, functional capacities, quality of life, neuropsychological aspects, patient satisfaction and healthcare resource consumption.Trial StatusTrial recruitment started in May 2012. As of September 2013, all 14 study centres have been initiated and 112/115 patients have been enrolled. Preliminary results are expected to be published in 2015.Trial RegistrationClinical trial registration information-URL: www.clinicaltrials.gov. Unique identifier NCT01628237.Copyright © 2014 Elsevier Masson SAS. All rights reserved.

32 keywords...

hide…